Sonja van Weely - Concepedia

Author

Sonja van Weely

University of Amsterdam

Also Known As

S Van Weely, S van Weely, S. Van Weely, S. van Weely, Sonja VAN WEELY, Sonja Van Weely, Sonja van Weely, van Weely, S.

Publications

Citations

H-Index

Concepts

All Affiliations

University of Amsterdam Amsterdam UMC Location University of Amsterdam Shaare Zedek Medical Center Centro de Genética Clínica Utrecht University

About

Sonja van Weely is an author at University of Amsterdam specializing in medicine, biochemistry, and glycobiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	3K
2	Biochemistry	10	10	1.4K
3	Natural Sciences	5	5	219
4	Health Sciences	2	2	927
5	Public Health	2	2	738

Sonja van Weely

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. Carla E. M. Hollak, Sonja van Weely, M. H. van Oers, Journal of Clinical Investigation Clinical SymptomsImmunologyGlycobiologyPathologyMarked Elevation	1994	899
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis Timothy M. Cox, Robin Lachmann, C. E. Hollak, The Lancet Ogt 918BiosynthesisMedicineSubstrate BiosynthesisMicrobiology	2000	740
The frequency of lysosomal storage diseases in The Netherlands Ben J. H. M. Poorthuis, Ron A. Wevers, Wim J. Kleijer, Human Genetics Lysosomal Storage DiseasesMendelian DisorderGenetic DisorderPathogenesisGenetic Epidemiology	1999	724
Sustained therapeutic effects of oral miglustat (Zavesca, <i>N</i>‐butyldeoxynojirimycin, OGT 918) in type I Gaucher disease Deborah Elstein, Carla E. M. Hollak, Johannes M. F. G. Aerts, Journal of Inherited Metabolic Disease	2004	231
Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease Sonja van Weely, Margreet Brandsma, Anneke Strijland, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Gaucher DiseaseBiochemistryGeneticsPathogenesisGlycobiology	1993	128
Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement Deborah Elstein, Altoon Dweck, Drorit Attias, Blood	2007	124
Low-Dose N-Butyldeoxynojirimycin (OGT 918) for Type I Gaucher Disease René Heitner, Deborah Elstein, Johannes M. F. G. Aerts, Blood Cells Molecules and Diseases Ogt 918Substrate Reduction TherapyPharmacotherapyAntimicrobial ChemotherapyMedicine	2002	97
Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease Helen Michelakakis, Cleopatra Spanou, A. P. Kondyli, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease InflammationAutoimmune DiseaseDisease MechanismImmunologyCell Death	1996	89
Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation Johannes M. F. G. Aerts, AndréW. Schram, Anneke Strijland, Biochimica et Biophysica Acta (BBA) - General Subjects Cellular EnzymologyBiochemistryNatural SciencesGlycobiologyMolecular Biology	1988	66
Quantitative Analysis of the Targeting of Mannose‐Terminal Glucocerebrosidase Martin K. Bijsterbosch, Wilma Donker, Hendrika van de Bilt, European Journal of Biochemistry Plasma Half-lifeTranslational MedicineBiochemistryMedicineTotal Liver Uptake	1996	62

Page 1